Manufacturer
NOVARTIS PHARMA STEIN A.G.
Contents
Canakinumab
Indication
Adult onset Still’s disease, Systemic onset juvenile chronic arthritis, Deficiency of mevalonate kinase, Hyper-immunoglobulin D periodic fever syndrome, Tumour necrosis factor receptor-associated periodic fever syndrome, Familial amyloid nephropathy with urticaria and deafness, Familial cold urticaria, Neonatal onset multisystem inflammatory disease, Familial Mediterranean fever, Acute gout.
Instruction
Administer via Subcutaneous.
Drug interaction
Increased risk of serious infections with tumour necrosis factor inhibitors.Potentially Fatal: May enhance the adverse/toxic effect and may diminish the therapeutic effect of live vaccines.
NOVARTIS PHARMA STEIN A.G.
Contents
Canakinumab
Indication
Adult onset Still’s disease, Systemic onset juvenile chronic arthritis, Deficiency of mevalonate kinase, Hyper-immunoglobulin D periodic fever syndrome, Tumour necrosis factor receptor-associated periodic fever syndrome, Familial amyloid nephropathy with urticaria and deafness, Familial cold urticaria, Neonatal onset multisystem inflammatory disease, Familial Mediterranean fever, Acute gout.
Instruction
Administer via Subcutaneous.
Drug interaction
Increased risk of serious infections with tumour necrosis factor inhibitors.Potentially Fatal: May enhance the adverse/toxic effect and may diminish the therapeutic effect of live vaccines.
Inquiry - Ilaris 150mg Powder for Solution for Injection